No abstract available.
Colitis ; Humans ; Immunosuppressive Agents

No abstract available.
Herpes Zoster* ; Humans ; Immunosuppressive Agents*

Study on white mices with age of 6-8 weeks, 18-20g body weight. They were divided into 3 groups: group 1 (control group): 30 mices; group 2: mices were immunesuppressed by 200mg cyclophosphamid per one kilogram of body weight, being checked after 5 days of injection; and 300mg cyclophosphamid per one kilogram (200mg on the first day and 100mg on the fifth day) and it was checked after 10 days of injection (group 3). The results: immunesuppressed model implemented by intraperitonial injection of 200mg per one kilogram of body weight checked after 5 days of injeciton. These parameters were used to assign the immune function
Immunosuppressive Agents ; Mice ; Animal Experimentation ; Cyclophosphamide

No abstract available.
Adult* ; Humans ; Immunosuppressive Agents* ; Nephrotic Syndrome*

No abstract available.
Cyclosporine ; Humans ; Immunosuppressive Agents* ; Psoriasis* ; Sarcoma, Kaposi*

No abstract available.
Cyclosporine ; Humans ; Immunosuppressive Agents* ; Psoriasis* ; Sarcoma, Kaposi*

Tacrolimus (FK506) is a 23-membered macrolide with immunosuppressant activity that is widely used clinically for treating the rejection after organ transplantation. The research on tacrolimus production was mainly focused on biosynthesis methods, within which there are still some bottlenecks. This review summarizes the progress made in tacrolimus biosynthesis via modification of metabolic pathways and control of fermentation process, with the hope to address the technical bottlenecks for tacrolimus biosynthesis and improve tacrolimus production by fermentation engineering and metabolic engineering.
Tacrolimus ; Immunosuppressive Agents ; Fermentation ; Macrolides ; Anti-Bacterial Agents

Multiple dermatofibromas are rare and some case reports show this disease has been related to generalized defective immune function: autoimmune disease and altered immunity, such as AIDS and systemic lupus erythematosus(SLE), can be treated with immunosuppressive agents. But there are no specific reports of this disease developing in healthy people. We describe a case of multiple dermatofibromas in a 38-year-old healthy man who showed no abnormality of the immune function.
Adult* ; Autoimmune Diseases ; Histiocytoma, Benign Fibrous* ; Humans ; Immunosuppressive Agents

Kaposi's sarcoma (KS) is a multifocal, systemic tumor of an endothelial cell origin and there are four clinical subtypes. Among these clinical subtypes, KS associated with immunosuppressive therapy mainly develops in organ transplant patients as well as in other patients who are receiving immunosuppressants for other reasons. It can occur from 1 month to more than 10 years after starting the agent and it seems to depend on the dose and type of the drug taken. We report here on a case of diffuse cutaneous iatrogenic Kaposi's sarcoma that was associated with 2 years of oral corticosteroid therapy. The patient's disease was present as various forms of cutaneous lesions without any systemic involvement.
Endothelial Cells ; Humans ; Immunosuppressive Agents ; Sarcoma, Kaposi ; Transplants

Necrotizing fasciitis (NF) is an uncommon, life-threatening infection of the subcutaneous tissue and superficial fascia. The clinical course of NF is rapid and progressive, and it is often fatal despite the appropriate therapy. The prognosis of NF depends on a timely diagnosis and then proper treatment. At onset it may not be possible to clearly distinguish NF from minor soft-tissue infections. Although infection are common due to the use of steroids and immunosuppressive agents in patients with systemic lupus erythematous (SLE), it is interesting that NF has rarely been reported with SLE. Here, we present two cases of NF with SLE.
Fasciitis, Necrotizing ; Humans ; Immunosuppressive Agents ; Prognosis ; Steroids ; Subcutaneous Tissue